Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,040 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung FT, Kuo CH, Lee KY, Lin SM, Lin HC, Wang CH, Yu CT, Kuo HP. Liu CY, et al. Among authors: wang ym, wang ch, wang cl. J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45. doi: 10.1007/s00432-009-0634-0. J Cancer Res Clin Oncol. 2010. PMID: 19572148
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status.
Hsu CH, Tseng CH, Chiang CJ, Hsu KH, Tseng JS, Chen KC, Wang CL, Chen CY, Yen SH, Chiu CH, Huang MS, Yu CJ, Tsai YH, Chen JS, Tsai CM, Chou TY, Lin KC, Tsai MH, Lee WC, Ku HY, Liu TW, Yang TY, Chang GC. Hsu CH, et al. Among authors: wang cl. Oncotarget. 2016 Jul 19;7(29):46628-46635. doi: 10.18632/oncotarget.9338. Oncotarget. 2016. PMID: 27191886 Free PMC article.
Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions.
Hsu PC, Chiu LC, Li SH, Chen CH, Wang CL, Kao KC, Chang JW, Wang CW, Yu CT, Chung FT, Yang CT, Liu CY. Hsu PC, et al. Among authors: wang cw, wang cl. Biomed J. 2016 Apr;39(2):121-9. doi: 10.1016/j.bj.2015.07.002. Epub 2016 Jun 9. Biomed J. 2016. PMID: 27372167 Free PMC article.
The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.
Liu CY, Wang CL, Li SH, Hsu PC, Chen CH, Lin TY, Kuo CH, Fang YF, Ko HW, Yu CT, Yang TY, Yang CT. Liu CY, et al. Among authors: wang cl. Oncotarget. 2017 Jun 27;8(57):97602-97612. doi: 10.18632/oncotarget.18746. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228636 Free PMC article.
2,040 results